Amgen 2010 Annual Report Download - page 87
Download and view the complete annual report
Please find page 87 of the 2010 Amgen annual report below. You can navigate through the pages in the report by either clicking on the pages listed below, or by using the keyword search tool below to find specific information within the annual report.-
1 -
2
-
3
-
4
-
5
-
6
-
7
-
8
-
9
-
10
-
11
-
12
-
13
-
14
-
15
-
16
-
17
-
18
-
19
-
20
-
21
-
22
-
23
-
24
-
25
-
26
-
27
-
28
-
29
-
30
-
31
-
32
-
33
-
34
-
35
-
36
-
37
-
38
-
39
-
40
-
41
-
42
-
43
-
44
-
45
-
46
-
47
-
48
-
49
-
50
-
51
-
52
-
53
-
54
-
55
-
56
-
57
-
58
-
59
-
60
-
61
-
62
-
63
-
64
-
65
-
66
-
67
-
68
-
69
-
70
-
71
-
72
-
73
-
74
-
75
-
76
-
77 -
78 -
79 -
80 -
81 -
82 -
83 -
84 -
85 -
86 -
87 -
88 -
89 -
90 -
91 -
92 -
93 -
94 -
95 -
96 -
97 -
98
-
99
-
100
-
101
-
102
-
103
-
104
-
105
-
106
-
107
-
108
-
109
-
110
-
111
-
112
-
113
-
114
-
115
-
116
-
117
-
118
-
119
-
120
-
121
-
122
-
123
-
124
-
125
-
126
-
127
-
128
-
129
-
130
-
131
-
132
-
133
-
134
-
135
-
136
-
137
-
138
-
139
-
140
-
141
-
142
-
143
-
144
-
145
-
146
-
147
-
148
-
149
-
150
-
151
-
152
-
153
-
154
-
155
-
156
-
157
-
158
-
159
-
160
-
161
-
162
-
163
-
164
-
165
-
166
-
167
-
168
-
169
-
170
-
171
-
172
-
173
-
174
-
175
-
176
 |
 |
Results of Operations
Product sales
For the years ended December 31, 2010, 2009 and 2008, worldwide product sales and total product sales by
geographic region were as follows (dollar amounts in millions):
2010 Change 2009 Change 2008
Aranesp»....................................... $ 2,486 (6)% $ 2,652 (15)% $ 3,137
EPOGEN»...................................... 2,524 (2)% 2,569 5% 2,456
Neulasta»/NEUPOGEN»............................ 4,844 4% 4,643 — 4,659
ENBREL ....................................... 3,534 1% 3,493 (3)% 3,598
Sensipar»/Mimpara»............................... 714 10% 651 9% 597
Vectibix»....................................... 288 24% 233 52% 153
Nplate»......................................... 229 — 110 — 17
Prolia»......................................... 33 — — — —
XGEVA
TM
....................................... 8 — — — —
Other .......................................... — — — — 70
Total product sales ............................. $14,660 2% $14,351 (2)% $14,687
Total U.S. ....................................... $11,254 1% $11,135 (3)% $11,460
Total International ................................. 3,406 6% 3,216 — 3,227
Total product sales ............................. $14,660 2% $14,351 (2)% $14,687
Product sales are influenced by a number of factors, some of which may impact the sales of certain of our
existing products more significantly than others, including, but not necessarily limited to:
• our contracting and pricing strategies;
• recent and future reimbursement changes resulting from:
lgovernmental or private organization regulations or guidelines relating to the use of our products;
llegislative reform in federal, state and foreign jurisdictions;
lcost containment pressures; and
lthe mix of reimbursement from governmental and private payers;
• clinical trial outcomes, including adverse events or results from clinical trials, including sub-analyses,
studies or meta-analyses performed by us or by others (including our licensees or independent investiga-
tors), which could impact product safety labeling and may negatively impact healthcare provider prescribing
behavior, use of our products, regulatory or private healthcare organization medical guidelines and
reimbursement practices;
• changes in clinical practice, including those resulting from the development of new protocols, tests and/or
treatments;
• adoption of and adherence to risk management activities, such as a REMS, undertaken by us or required by
the FDA or other regulatory authorities;
• product label changes;
• patient population growth;
• segment growth and penetration;
• new product launches and indications;
• expansion into new international markets;
71